NFKB1 and Miyoshi myopathy: Pirh2 inhibits the NF-κB signaling pathway by inhibiting the phosphorylation and subsequent degradation of IKBa to overcome acquired bortezomib resistance in MM cells (L. Yang et al., 2018).